VECIMA-NETWORKS
Vecima Networks Inc. (TSX: VCM) will showcase industry leadership at ANGA COM 2023, with technology demonstrations and panel presentations highlighting 10G PON fiber access solutions, Remote PHY (R-PHY) and Remote MACPHY (R-MACPHY) solutions, and next-generation video solutions, including Open CDN and Dynamic Content.
Technologies to be on display
Named by Dell’Oro Group as the global market share leader for Remote Optical Line Terminals (OLTs), Vecima expands its fiber access portfolio with a flexible, compact, and powerful shelf-based platform that supports all predominantly deployed Passive Optical Network (PON) variants. The Entra® EXS1610 All-PON™ Shelf allows customers to selectively deploy Distributed Access Architecture (DAA) and fiber to the home in any market or hub deployment, allowing maximum flexibility to deploy Cable Access and Fiber Access solutions based on specific subscriber need.
The Entra® EN2112 R-PHY Access Node is a high-density, compact, two-port node that’s interoperable with third-party converged cable access platform (CCAP) cores and vCMTS (virtual cable modem termination systems), creating an open, flexible DAA ecosystem. Supporting architectures that push fiber deeper into the network, the EN2112 allows operators to optimize existing hybrid fiber-coax (HFC) network capacity and deliver increased bandwidth to subscribers. Vecima recently announced that Kbro, Taiwan’s largest cable operator, selected the EN2112 R-PHY Node as part of its DAA solution to enable high-speed DOCSIS® 3.1 services for its subscribers.
The Entra® ERM3 Remote PHY Device (RPD) is designed to easily upgrade existing HFC nodes to DAA, reduce installation time, and lower operating costs for service providers while dramatically increasing broadband capacity. The ERM3 RPD boasts a unique form factor and features, highlighting Vecima’s open and interoperable approach to hardware and software. Like all RPDs in Vecima’s lineup, the ERM3 is interoperable with vCMTS and third-party CCAP cores. Vecima recently announced Charter Communications selected the ERM3 to enable 10G services over HFC networks.
The Entra® SC-1D Entra Access Node offers a Remote MACPHY/R-MACPHY Device in a compact, European form factor. Part of Vecima’s DAA solution that’s deployed in Europe, the SC-1D enables operators to deploy gigabit broadband and new services to residential subscribers and businesses. In addition, moving to DAA delivers sustainability through digitization, enabling substantial energy savings. Dell’Oro Group recently named Vecima as the global revenue share leader in Remote MACPHY devices.
Vecima’s MediaScale™ Streaming solutions, including Open CDN for high-quality, congestion-free streaming that’s more cost-effective and efficient, and Dynamic Content with Ad Insertion for highly targeted ads and more value per impression.
MediaScale Open CDN can be provisioned via Open Caching APIs to deliver and cache video content on behalf of the provisioning upstream provider’s content delivery network. It helps service providers monetize the terabytes of internet traffic delivered free of charge today and prepare their networks for the petabytes of content yet to come. The subscriber gets an improved viewing experience, without the headache of rebuffering and poor video quality.
Service providers can gain control over content with the MediaScale Dynamic Content solution which supports content rights, blackouts, and advertising. By manipulating content at the edge of the network, operators can deliver more efficient, personalized video content and more opportunities to monetize that content with targeted, higher-value ads.
Vecima speakers at ANGA COM
Vecima’s Chris Busch, Principal Architect Office of CTO, will speak on “Fiber Access and Measuring QoE – Taking a Slice of the Access Network” on Wednesday, May 24.
Quotes from Vecima executives attending ANGA COM
“Operators in the region need flexibility as they expand their networks and plan for future services, and Vecima’s portfolio provides multiple options to get to 10G,” said John Ruwe, Vice President of EMEA Sales at Vecima. “Vecima continues to increase our footprint in the European market, and we look forward to showcasing our technology leadership at ANGA COM.”
“Vecima is helping operators around the world evolve their networks with 10G-capable fiber and cable access solutions that prime them for future growth,” said Clay McCreery, Chief Operating Officer at Vecima. “We’re leading the way in delivering limitless broadband connectivity and content-rich video experiences across Europe and around the world.”
Visit Vecima Networks at ANGA COM 2023
May 23-25 in Cologne, Germany
Koelnmesse Hall 8, Stand D40
To schedule a meeting with the Vecima team, contact us at sales@vecima.com.
Media and industry analysts, please contact bernadette.dunn@vecima.com.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multigigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005294/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom